<DOC>
	<DOCNO>NCT00868114</DOCNO>
	<brief_summary>This research study use radiation gene therapy agent , TNFerade addition dendritic cell vaccine patient locally advance low volume metastatic pancreatic cancer . The use TNFerade radiation serf generate cell death stimulate immune response . The dendritic cell vaccine may direct distant last effective anti-tumor immune response achieve local systemic clinical benefit .</brief_summary>
	<brief_title>Direct Tumor Injection KLH-Pulsed Dendritic Cells Unresectable Pancreatic Cancer</brief_title>
	<detailed_description />
	<mesh_term>Pancreatic Neoplasms</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Biopsy proven , unresectable pancreatic cancer intact primary tumor accessible direct intratumoral injection Low volume metastatic disease define 1 ) radiographically occult disease discover time anticipated resection 2 ) 4 radiographically detected metastasis none great 2 cm great dimension Good overall health Karnofsky performance status 70 % great No evidence history autoimmune dysfunction Life expectancy &gt; 3 month Agreement initiate complete standard treatment ( chemotherapy ± radiation ) pancreatic cancer completion study Age equal great 18 year No prior concurrent chemotherapy No previous concurrent immunotherapy pancreatic cancer Liver enzymes ≤ 3 time upper limit normal : Tbili ≤ 3.9 ( biliary stent allow ) AST ≤ 177 ALT ≤ 198 Alk phos ≤ 378 Adequate pretreatment organ function : Creatinine great 1.5mg/dL Total calcium great 11.0mg/dL PT great 14 second PTT great 40 second Ability give inform consent Adequate baseline hematopoietic function : Total white blood cell count equal great 3,000/mm3 ; Absolute granulocyte count great 1,500/mm3 ; Absolute lymphocyte count great 500/mm3 ; Platelet count equal great 100,000/mm3 . Prior history XRT primary pancreatic tumor Patients tumor accessible direct access include study , patient poor overall health determine standard laboratory data performance scale Prior concurrent chemotherapy Prior history ( within last four week ) antineoplastic therapy irradiation Prior treatment antitumor vaccine allow Patients history autoimmune diseases SLE , rheumatoid arthritis myasthenia gravis A history HIV infection , AIDS immunosuppressive disease state Patients require regular corticosteroid within past year ineligible . There must use corticosteroid fours week precede entry study Active bacterial , fungal viral infection Active bleeding ( hemoptysis , melena , etc ) Women currently pregnant actively breast feeding . Women childbearing potential must negative serum pregnancy test must use effective contraception trial participation Uncontrolled unstable medical condition , include angina , bronchospasm , hypertension , hyperglycemia , hypercalcemia cardiac arrhythmia Any medical psychiatric illness opinion principal investigator might compromise patient 's ability tolerate complete treatment Patients require anticoagulation ineligible Refusal receive standard treatment ( chemotherapy ± radiation ) completion protocol Evidence DVT prior history DVT</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2014</verification_date>
	<keyword>Inoperable pancreatic cancer</keyword>
	<keyword>Dendritic Cell Vaccine</keyword>
	<keyword>Locally advanced low volume metatstatic pancreatic cancer</keyword>
</DOC>